Credit ratings of Novartis AG
| Moody’s Investors Service | S&P Global Ratings | |
|---|---|---|
| Short term | P-1 | A-1+ |
| Long term | Aa3 | AA- |
| Outlook | Stable | Stable |
USD fixed-income securities
| Issuer | Amount (in millions) | Coupon | Maturity |
|---|---|---|---|
| Novartis Capital Corp. | 1,750 | 3.000% | 2025 |
| Novartis Capital Corp. | 1,250 | 2.000% | 2027 |
| Novartis Capital Corp. | 1,000 | 3.100% | 2027 |
| Novartis Capital Corp. | 1,000 | 3.800% | 2029 |
| Novartis Capital Corp. | 1,500 | 2.200% | 2030 |
| Novartis Capital Corp. | 850 | 4.000% | 2031 |
| Novartis Capital Corp. | 1,100 | 4.200% | 2034 |
| Novartis Capital Corp. | 500 | 3.700% | 2042 |
| Novartis Capital Corp. | 1,850 | 4.400% | 2044 |
| Novartis Capital Corp. | 1,250 | 4.000% | 2045 |
| Novartis Capital Corp. | 1,250 | 2.750% | 2050 |
| Novartis Capital Corp. | 750 | 4.700% | 2054 |
Novartis Capital Corp.
| Principal amount | USD 1,750,000,000 |
| ISIN | US66989HAJ77 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 3.000% |
| Coupon payment date | May 20 and November 20, commencing May 20, 2016 |
| Documentation | SEC registered shelf registration |
| First settlement date | November 20, 2015 |
| Issue price | 99.010 |
| Maturity date | November 20, 2025 |
| Joint book-runners | Bank of America Merrill Lynch, Citi, JP Morgan, Credit Suisse, Goldman Sachs, UBS |
| Bloomberg | NOVNVX 3 11/20/2025 |
Novartis Capital Corp.
| Principal amount | USD 1,250,000,000 |
| ISIN | US66989HAQ11 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 2.000% |
| Coupon payment date | February 14 and August 14, commencing August 14, 2020 |
| Documentation | SEC registered shelf registration |
| First settlement date | February 14, 2020 |
| Issue price | 99.909 |
| Maturity date | February 14, 2027 |
| Joint book-runners | Citi, HSBC, Morgan Stanley, Mitsubishi UFJ Financial Group, Barclays, Deutsche Bank, Mizuho |
| Bloomberg | NOVNVX 2.0 02/14/2027 |
Novartis Capital Corp.
| Principal amount | USD 1,000,000,000 |
| ISIN | US66989HAN89 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 3.100% |
| Coupon payment date | May 17 and November 17, commencing May 17, 2017 |
| Documentation | SEC registered shelf registration |
| First settlement date | February 17, 2017 |
| Issue price | 99.109 |
| Maturity date | May 17, 2027 |
| Joint book-runners | Bank of America Merrill Lynch, Citi, JP Morgan, Credit Suisse, Goldman Sachs, UBS |
| Bloomberg | NOVNVX 3.1 05/17/2027 |
Novartis Capital Corp.
| Principal amount | USD 1,000,000,000 |
| ISIN | US66989HAT59 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 3.800% |
| Coupon payment date | March 18 and September 18, commencing March 18, 2025 |
| Documentation | SEC registered shelf registration |
| First settlement date | September 18, 2024 |
| Issue price | 99.757 |
| Maturity date | September 18, 2029 |
| Joint book-runners | Goldman Sachs, JP Morgan, Citi, Mizuho, Barclays, HSBC, Société Générale |
| Bloomberg | NOVNVX 3.80 09/18/2029 |
Novartis Capital Corp.
| Principal amount | USD 1,500,000,000 |
| ISIN | US66989HAR93 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 2.200% |
| Coupon payment date | February 14 and August 14, commencing August 14, 2020 |
| Documentation | SEC registered shelf registration |
| First settlement date | February 14, 2020 |
| Issue price | 99.869 |
| Maturity date | August 14, 2030 |
| Joint book-runners | Citi, HSBC, Morgan Stanley, Mitsubishi UFJ Financial Group, Barclays, Deutsche Bank, Mizuho |
| Bloomberg | NOVNVX 2.2 08/14/2030 |
Novartis Capital Corp.
| Principal amount | USD 850,000,000 |
| ISIN | US66989HAU23 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 4.000% |
| Coupon payment date | March 18 and September 18, commencing March 18, 2025 |
| Documentation | SEC registered shelf registration |
| First settlement date | September 18, 2024 |
| Issue price | 99.565 |
| Maturity date | September 18, 2031 |
| Joint book-runners | Goldman Sachs, JP Morgan, Citi, Mizuho, Barclays, HSBC, Société Générale |
| Bloomberg | NOVNVX 4.00 09/18/2031 |
Novartis Capital Corp.
| Principal amount | USD 1,100,000,000 |
| ISIN | US66989HAV06 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 4.200% |
| Coupon payment date | March 18 and September 18, commencing March 18, 2025 |
| Documentation | SEC registered shelf registration |
| First settlement date | September 18, 2024 |
| Issue price | 99.282 |
| Maturity date | September 18, 2034 |
| Joint book-runners | Goldman Sachs, JP Morgan, Citi, Mizuho, Barclays, HSBC, Société Générale |
| Bloomberg | NOVNVX 4.20 09/18/2034 |
Novartis Capital Corp.
| Principal amount | USD 500,000,000 |
| ISIN | US66989HAF55 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 3.700% |
| Coupon payment date | March 21 and September 21, commencing March 21, 2013 |
| Documentation | SEC registered shelf registration |
| First settlement date | September 21, 2012 |
| Issue price | 98.325 |
| Maturity date | September 21, 2042 |
| Joint book-runners | JP Morgan, Morgan Stanley, BNP Paribas, Citi, Bank of America Merrill Lynch, UBS |
| Bloomberg | NOVNVX 3.7 09/21/42 |
Novartis Capital Corp.
| Principal amount | USD 1,850,000,000 |
| ISIN | US66989HAH12 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 4.400% |
| Coupon payment date | May 6 and November 6, commencing May 6, 2014 |
| Documentation | SEC registered shelf registration |
| First settlement date | February 21, 2014 |
| Issue price | 99.196 |
| Maturity date | May 6, 2044 |
| Joint book-runners | Goldman Sachs, Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, JP Morgan |
| Bloomberg | NOVNVX 4.4 05/06/44 |
Novartis Capital Corp.
| Principal amount | USD 1,250,000,000 |
| ISIN | US66989HAK41 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 4.000% |
| Coupon payment date | May 20 and November 20, commencing May 20, 2016 |
| Documentation | SEC registered shelf registration |
| First settlement date | November 20, 2015 |
| Issue price | 98.029 |
| Maturity date | November 20, 2045 |
| Joint book-runners | Bank of America Merrill Lynch, Citi, JP Morgan, Credit Suisse, Goldman Sachs, UBS |
| Bloomberg | NOVNVX 4 11/20/2045 |
Novartis Capital Corp.
| Principal amount | USD 1,250,000,000 |
| ISIN | US66989HAS76 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 2.750% |
| Coupon payment date | February 14 and August 14, commencing August 14, 2020 |
| Documentation | SEC registered shelf registration |
| First settlement date | February 14, 2020 |
| Issue price | 97.712 |
| Maturity date | August 14, 2050 |
| Joint book-runners | Citi, HSBC, Morgan Stanley, Mitsubishi UFJ Financial Group, Barclays, Deutsche Bank, Mizuho |
| Bloomberg | NOVNVX 2.75 08/14/2050 |
Novartis Capital Corp.
| Principal amount | USD 750,000,000 |
| ISIN | US66989HAW88 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 4.700% |
| Coupon payment date | March 18 and September 18, commencing March 18, 2025 |
| Documentation | SEC registered shelf registration |
| First settlement date | September 18, 2024 |
| Issue price | 99.936 |
| Maturity date | September 18, 2054 |
| Joint book-runners | Goldman Sachs, JP Morgan, Citi, Mizuho, Barclays, HSBC, Société Générale |
| Bloomberg | NOVNVX 4.70 09/18/2054 |
CHF fixed-income securities
| Issuer | Amount (in millions) | Coupon | Maturity |
|---|---|---|---|
| Novartis AG | 650 | 1.600% | 2027 |
| Novartis AG | 550 | 0.625% | 2029 |
| Novartis AG | 435 | 1.650% | 2031 |
| Novartis AG | 645 | 1.750% | 2034 |
| Novartis AG | 325 | 1.050% | 2035 |
| Novartis AG | 280 | 1.850% | 2040 |
| Novartis AG | 190 | 1.850% | 2049 |
Novartis AG
| Principal amount | CHF 650,000,000 |
| ISIN | CH1353257806 |
| Issuer | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 1.600% |
| Coupon payment date | June 18 |
| Documentation | Swiss stand-alone documentation |
| First settlement date | June 18, 2024 |
| Issue price | 100.138 |
| Maturity date | June 18, 2027 |
| Joint book-runners | BNP Paribas, Deutsche Bank, UBS |
| Bloomberg | NOVNVX 1.6 6/18/27 |
| Listing | SIX Swiss Exchange |
Novartis AG
| Principal amount | CHF 550,000,000 |
| ISIN | CH0270190991 |
| Issuer | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 0.625% |
| Coupon payment date | November 13 |
| Documentation | Swiss stand-alone documentation |
| First settlement date | February 13, 2015 |
| Issue price | 100.502 |
| Maturity date | November 13, 2029 |
| Joint book-runners | Credit Suisse, UBS |
| Bloomberg | NOVNVX 0.625 11/13/29 |
| Listing | SIX Swiss Exchange |
Novartis AG
| Principal amount | CHF 435,000,000 |
| ISIN | CH1353257814 |
| Issuer | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 1.650% |
| Coupon payment date | June 18 |
| Documentation | Swiss stand-alone documentation |
| First settlement date | June 18, 2024 |
| Issue price | 100.148 |
| Maturity date | June 18, 2031 |
| Joint book-runners | BNP Paribas, Deutsche Bank, UBS |
| Bloomberg | NOVNVX 1.65 6/18/31 |
| Listing | SIX Swiss Exchange |
Novartis AG
| Principal amount | CHF 645,000,000 |
| ISIN | CH1353257822 |
| Issuer | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 1.750% |
| Coupon payment date | June 16 |
| Documentation | Swiss stand-alone documentation |
| First settlement date | June 18, 2024 |
| Issue price | 100.229 |
| Maturity date | June 16, 2034 |
| Joint book-runners | BNP Paribas, Deutsche Bank, UBS |
| Bloomberg | NOVNVX 1.75 6/16/34 |
| Listing | SIX Swiss Exchange |
Novartis AG
| Principal amount | CHF 325,000,000 |
| ISIN | CH0270191007 |
| Issuer | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 1.050% |
| Coupon payment date | May 11 |
| Documentation | Swiss stand-alone documentation |
| First settlement date | February 13, 2015 |
| Issue price | 100.479 |
| Maturity date | May 11, 2035 |
| Joint book-runners | Credit Suisse, UBS |
| Bloomberg | NOVNVX 1.05 05/11/35 |
| Listing | SIX Swiss Exchange |
Novartis AG
| Principal amount | CHF 280,000,000 |
| ISIN | CH1353257830 |
| Issuer | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 1.850% |
| Coupon payment date | June 18 |
| Documentation | Swiss stand-alone documentation |
| First settlement date | June 18, 2024 |
| Issue price | 100.268 |
| Maturity date | June 18, 2040 |
| Joint book-runners | BNP Paribas, Deutsche Bank, UBS |
| Bloomberg | NOVNVX 1.85 6/18/40 |
| Listing | SIX Swiss Exchange |
Novartis AG
| Principal amount | CHF 190,000,000 |
| ISIN | CH1353257848 |
| Issuer | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 1.850% |
| Coupon payment date | June 18 |
| Documentation | Swiss stand-alone documentation |
| First settlement date | June 18, 2024 |
| Issue price | 100.149 |
| Maturity date | June 18, 2049 |
| Joint book-runners | BNP Paribas, Deutsche Bank, UBS |
| Bloomberg | NOVNVX 1.85 6/18/49 |
| Listing | SIX Swiss Exchange |
EUR fixed-income securities
| Issuer | Amount (in millions) | Coupon | Maturity |
|---|---|---|---|
| Novartis Finance S.A. | 600 | 1.625% | 2026 |
| Novartis Finance S.A. | 600 | 1.125% | 2027 |
| Novartis Finance S.A. | 500 | 0.625% | 2028 |
| Novartis Finance S.A. | 1,850 | 0.000% | 2028 |
| Novartis Finance S.A. | 750 | 1.375% | 2030 |
| Novartis Finance S.A. | 750 | 1.700% | 2038 |
Novartis Finance S.A.
| Principal amount | EUR 600,000,000 |
| ISIN | XS1134729794 |
| Issuer | Novartis Finance S.A., Luxembourg |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 1.625% |
| Coupon payment date | November 09 |
| Documentation | Standalone |
| First settlement date | November 07, 2014 |
| Issue price | 99.697 |
| Maturity date | November 09, 2026 |
| Joint book-runners | Barclays, BNP Paribas, Deutsche Bank |
| Bloomberg | NOVNVX 1.625 11/09/26 |
| Listing | SIX Swiss Exchange |
Novartis Finance S.A.
| Principal amount | EUR 600,000,000 |
| ISIN | XS1585010074 |
| Issuer | Novartis Finance S.A., Luxembourg |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 1.125% |
| Coupon payment date | September 30, commencing September 30, 2017 |
| Documentation | Standalone |
| First settlement date | March 31, 2017 |
| Issue price | 99.874 |
| Maturity date | September 30, 2027 |
| Joint book-runners | Barclays, BNP Paribas, Deutsche Bank |
| Bloomberg | NOVNVX 1.125 09/30/27 |
| Listing | SIX Swiss Exchange |
Novartis Finance S.A.
| Principal amount | EUR 500,000,000 |
| ISIN | XS1492825481 |
| Issuer | Novartis Finance S.A., Luxembourg |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 0.625% |
| Coupon payment date | September 20 |
| Documentation | Standalone |
| First settlement date | September 20, 2016 |
| Issue price | 98.48 |
| Maturity date | September 20, 2028 |
| Joint book-runners | Barclays, BNP Paribas, Deutsche Bank |
| Bloomberg | NOVNVX 0.625 09/20/28 |
| Listing | SIX Swiss Exchange |
Novartis Finance S.A.
| Principal amount | EUR 1,850,000,000 |
| ISIN | XS2235996217 |
| Issuer | Novartis Finance S.A., Luxembourg |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 0.000% |
| Coupon step-up | Coupon to increase by 25 basis points from 2026 onwards if Novartis does not achieve the 2025 Patient Access Targets |
| Coupon payment date | September 23 |
| Documentation | Standalone |
| First settlement date | September 23, 2020 |
| Issue price | 99.354 |
| Maturity date | September 23, 2028 |
| Joint book-runners | Barclays, HSBC, J.P. Morgan, Societe Generale |
| Bloomberg | NOVNVX 0 09/23/28 |
| Listing | SIX Swiss Exchange |
Novartis Finance S.A.
| Principal amount | EUR 750,000,000 |
| ISIN | XS1769041192 |
| Issuer | Novartis Finance S.A., Luxembourg |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 1.375% |
| Coupon payment date | August 14 |
| Documentation | Standalone |
| First settlement date | February 14, 2018 |
| Issue price | 99.957 |
| Maturity date | August 14, 2030 |
| Joint book-runners | Barclays, BNP Paribas, Deutsche Bank |
| Bloomberg | NOVNVX 1.375 08/14/30 |
| Listing | SIX Swiss Exchange |
Novartis Finance S.A.
| Principal amount | EUR 750,000,000 |
| ISIN | XS1769041606 |
| Issuer | Novartis Finance S.A., Luxembourg |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 1.700% |
| Coupon payment date | August 14 |
| Documentation | Standalone |
| First settlement date | February 14, 2018 |
| Issue price | 99.217 |
| Maturity date | August 14, 2038 |
| Joint book-runners | Barclays, BNP Paribas, Deutsche Bank |
| Bloomberg | NOVNVX 1.7 08/14/38 |
| Listing | SIX Swiss Exchange |